4 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
hepatitis and communicating data from key R&D programs focused on Wnt modulation at upcoming medical meetings and in publications,” said Craig Parker
8-K
EX-99.2
SRZN
Surrozen Inc
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
Surrozen, Inc.
Wnt Biology Drives R&D Pipeline Program Indication Research Preclinical Phase 1 Phase 2 Phase 3 Partnerships Status SZN-043 Severe
8-K
EX-99.2
SRZN
Surrozen Inc
12 Aug 21
Regulation FD Disclosure
11:52am
Expertise Supports Productive R&D Pipeline IND Enabling Studies Ongoing for SZN-1326 and SZN-043; Planned Phase 1 Clinical Trials 2022 Lead LEAD NEXT … Productive R&D Pipeline IND Enabling Studies Ongoing for SZN-1326 and SZN-043; Planned Phase 1 Clinical Trials 2022 Lead LEAD NEXT INDICATION/S
S-4/A
EX-10.17
SRZN
Surrozen Inc
24 Jun 21
Registration of securities issued in business combination transactions (amended)
5:13pm
, infringes, induces infringement, or contributes to infringement of a Valid Claim.
“Licensed R&D Field of Use” means the conduct of research and development … , the amount paid to Stanford [****]
“Other Field of Use” means all fields other than the Licensed Field of Use and the Licensed R&D Field of Use
- Prev
- 1
- Next